Abstract:OBJECTIVE:To identify the effect of postoperative adjuvant transarterial chemoembolization (TACE) on late recurrence of hepatocellular carcinoma (HCC) patients after radical resection. METHODS:From year 2001 to 2007, 2436 HCC patients underwent radical resection were retrospectively selected. Patients underwent resection only were classified into control group, while those received adjuvant TACE within 2 months after operation were classified into intervention group. Patients were further stratified into those with tumor5 cm and presenting low or high risk factors for recurrence. Patients with single tumor and without microscopic tumor thrombus were defined as low risk for recurrence; otherwise they were defined as high risk. The effect of adjuvant TACE on late (>2 years) recurrence was evaluated. RESULTS:Recurrence rates of tumor5 cm and presenting low, high risk factors for recurrence at 2-year after resection were 20.38%, 33.06%, 30.54% and 50.82%, respectively in the control group, compared with 25.41%, 39.61%, 40.55% and 51.57%, respectively in the intervention group; there were no significant differences between intervention group and control group in each stratum. For patients recurred or died within the first 2 years after resection, the median survival of tumor>5 cm and presenting high risk factors for recurrence was 24 months in the intervention group and 12 months in the Control group. Only in this subgroup, the survival curve of the intervention group was significantly higher than that compared to the control group. For patients who remained recurrence free and survived within the first 2 years after resection, there were no significant differences in the recurrence curves between the intervention group and control group in each stratum; while cumulative survival rates in the subgroup of patients with tumor size is less than or equal to 5 cm and presenting low risk factors for recurrence were 93.95%, 91.50% and 88.42% respectively in the control group, compared with 91.70%, 81.32% and 78.19% respectively in the intervention group at 3-, 4- and 5-year after resection (P=0.0062); for other subgroups, there were no significant differences in the survival curves between the intervention group and the control group in each stratum. Cox regression model suggested adjuvant TACE was not an independent risk factor for late recurrence; however, it might have negative effect on survival [hazard ratio (HR)=1.50, P=0.062] for those patients (especially patients with tumor is less than or equal to 5 cm and presenting low risk factors for recurrence). CONCLUSIONS:The value of adjuvant TACE was mainly due to its therapeutic actions on residual tumor or early recurrence. It had no effect on postponing or eliminating late recurrence; moreover, it could be a risk rather than a benefit in patients at low risk for recurrence (especially those with tumor is less than or equal to 5 cm and presenting low risk factors for recurrence).

Postoperative Transarterial Chemoembolization on Patients with Hepatocellular Carcinoma:A Systematic Review

Evaluation of the Curative Effect of Transcatheter Arterial Chemoembolization Via Hepatic Artery Combined with Percutaneous Ethanol Injection for the Treatment of Primary Hepatocellular Carcinoma

A Systematic Review and Meta-Analysis of Adjuvant Transarterial Chemoembolization after Curative Resection for Patients with Hepatocellular Carcinoma

Transarterial Chemoembolization As an Adjuvant Therapy in Patients with Hepatocellular Carcinoma Treated with Hepatectomy

Adjuvant transarterial chemoembolization to improve the prognosis of hepatocellular carcinoma following curative resection

[Effect of Postoperative Transcatheter Arterial Chemoembolization on Hepatocellular Carcinoma Patients with Residual Tumor].

Adjuvant Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma

[Transcatheter Hepatic Arterial Chemoembolization on Recurrent Hepatocellular Carcinoma after Resection].

Postoperative Adjuvant Arterial Chemoembolization Improves Survival of Hepatocellular Carcinoma Patients with Risk Factors for Residual Tumor: a Retrospective Control Study.

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Repeated Postoperative Adjuvant TACE after Curative Hepatectomy Improves Outcomes of Patients with HCC

[Effect of Postoperative Adjuvant Transarterial Chemoembolization on Late Recurrence of Hepatocellular Carcinoma after Radical Resection].

The influence of postoperative TACE on the survival time and prognosis in hepatocellular carcinoma patients after liver resection

Efficacy of Transarterial Chemoembolisation with or Without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy

The effect of postoperative adjuvant transcatheter hepatic arterial chemoembolization on survival of patients after resection of huge hepatocellular carcinoma

Hepatic Resection for Hepatocellular Carcinoma with or Without Postoperative Adjuvant Transarterial Chemoembolization: a Comparative Study

Efficacy and Safety of Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Postoperative Adjuvant Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma: Friend or Foe? a Meta Analysis

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis

Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma

Efficacy of traditional herbal medicine versus transcatheter arterial chemoembolization in postsurgical patients with hepatocellular carcinoma: A retrospective study